Literature DB >> 15667712

Effect of renal impairment on the pharmacokinetics of antimony in hamsters.

I Y Zaghloul1, M Al-Jasser.   

Abstract

Renal failure was experimentally induced in 36 hamsters by intraperitoneal injection with uranyl nitrate (5 mg/kg). Twenty-four h later [during acute renal failure (ARF), as indicated by the serum concentrations of creatinine and urea nitrogen] or 72 h later [during chronic renal failure (CRF)] these hamsters plus 18, uninjected, control hamsters were each given a single, intramuscular dose of sodium stibogluconate (120 mg pentavalent antimony/kg). The pharmacokinetic parameters for the antimonial drug were calculated using a non-compartmental model. Urine was collected for 72 h after similar treatment with the antimonial drug, from another 30 hamsters (10 controls, 10 with ARF, and 10 with CRF), so that the fraction of the antimony administered that was subsequently excreted in the urine could be estimated. Compared with the controls, both the hamsters with ARF and those with CRF had significantly higher maximum concentrations of antimony (C(max)), significantly larger 'areas under the curve' for the plots of blood concentration v. time, and significantly longer plasma half-lives (P < 0.001 for each). The mean (S.D.) values of C(max), for example, were more than three-fold higher in the hamsters with ARF [467.5 (59.04) microg/ml] or CRF [461.1 (68.9) microg/ml] than in the controls [154.01 (17.3) microg/ml]. The systemic clearance of antimony was also significantly lower in the hamsters with CRF than in the control animals [0.051 (0.002) v. 0.296 (0.047) litres/h/kg; P < 0.01]. In addition, the fraction of the antimony administered that was excreted in urine was significantly lower in the animals with ARF (0.25) or CRF (0.08) than in the controls (0.37), indicating significant dysfunction of the kidneys in the hamsters injected with uranyl nitrate. It seems clear that, if severe toxicity is to be avoided, patients with renal dysfunction requiring treatment (for leishmaniasis) with sodium stibogluconate should be given lower doses than similar cases with normal kidney function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15667712     DOI: 10.1179/000349804X3171

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  6 in total

1.  Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.

Authors:  Mohini Chaurasia; Pankaj K Singh; Anil K Jaiswal; Animesh Kumar; Vivek K Pawar; Anuradha Dube; Sarvesh K Paliwal; Manish K Chourasia
Journal:  Pharm Res       Date:  2016-07-11       Impact factor: 4.200

Review 2.  Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Authors:  Lucio H Freitas-Junior; Eric Chatelain; Helena Andrade Kim; Jair L Siqueira-Neto
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-01-28       Impact factor: 4.077

Review 3.  Leishmaniasis: where are we and where are we heading?

Authors:  Santanu Sasidharan; Prakash Saudagar
Journal:  Parasitol Res       Date:  2021-04-07       Impact factor: 2.289

4.  Management of canine leishmaniosis in endemic SW European regions: a questionnaire-based multinational survey.

Authors:  Patrick Bourdeau; Manolis N Saridomichelakis; Ana Oliveira; Gaetano Oliva; Tina Kotnik; Rosa Gálvez; Valentina Foglia Manzillo; Alex F Koutinas; Isabel Pereira da Fonseca; Guadalupe Miró
Journal:  Parasit Vectors       Date:  2014-03-24       Impact factor: 3.876

Review 5.  Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Wendel Coura-Vital; Henrique Gama Ker; Nádia das Dores Moreira; Juliana Vitoriano-Souza; Rodolfo Cordeiro Giunchetti; Cláudia Martins Carneiro; Alexandre Barbosa Reis
Journal:  Front Immunol       Date:  2014-06-13       Impact factor: 7.561

6.  Anti-Leishmanial Activity (In Vitro and In Vivo) of Allicin and Allicin Cream Using Leishmania major (Sub-strain Zymowme LON4) and Balb/c Mice.

Authors:  Dina M Metwally; Ebtesam M Al-Olayan; Manal F El-Khadragy; Badriah Alkathiri
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.